Patterns and Outcome of Autoimmune Related Liver Disease

NCT03898414 | Completed

• 1 other identifier: autoimmune liver disease
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Study of the different patterns of autoimmune related chronic liver disease to assess the prevalence of various types and outcome of treatment of autoimmune related chronic liver disease

Conditions

Autoimmune Liver Disease

Outcome Measures

Primary Outcomes (1)

• Evaluation of patterns of autoimmune chronic liver diseases

  Evaluation of patterns of autoimmune chronic liver diseasesupport and outcome of treagent of these diseases

  2013-2019

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Patients 18-60 years old with autoimmune related chronic liver disease

You may qualify if:

• Patients that will fulfill the following criteria will be enrolled:
• Patients diagnosed as AIH According to the simplified criteria of AIH scoring
• Patients diagnosed as PBC or PSC according to the Amiracan association of study of liver disease (AASLD) - For all enrolled patients the presentation, treatment history, and outcome of treatment will be evaluated.

You may not qualify if:

• All patients with chronic liver disease other than autoimmune liver disease will be excluded

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Assiut university hospitals

Asyut, Egypt

Location

Related Publications (6)

• Lee YM, Teo EK, Ng TM, Khor C, Fock KM. Autoimmune hepatitis in Singapore: a rare syndrome affecting middle-aged women. J Gastroenterol Hepatol. 2001 Dec;16(12):1384-9. doi: 10.1046/j.1440-1746.2001.02646.x.

  PMID: 11851837 BACKGROUND

• Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I, Baldo V, Premoli A, Olivero F, Morello E, Durazzo M. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther. 2006 Oct 1;24(7):1051-7. doi: 10.1111/j.1365-2036.2006.03104.x.

  PMID: 16984499 BACKGROUND

• Kumagi T, Alswat K, Hirschfield GM, Heathcote J. New insights into autoimmune liver diseases. Hepatol Res. 2008 Aug;38(8):745-61. doi: 10.1111/j.1872-034X.2008.00366.x. Epub 2008 May 7.

  PMID: 18462376 BACKGROUND

• Fallatah HI, Akbar HO, Qari YA. Autoimmune hepatitis: Single-center experience of clinical presentation, response to treatment and prognosis in Saudi Arabia. Saudi J Gastroenterol. 2010 Apr-Jun;16(2):95-9. doi: 10.4103/1319-3767.61235.

  PMID: 20339178 BACKGROUND

• Hirschfield GM, Al-Harthi N, Heathcote EJ. Current status of therapy in autoimmune liver disease. Therap Adv Gastroenterol. 2009 Jan;2(1):11-28. doi: 10.1177/1756283X08098966.

  PMID: 21180531 BACKGROUND

• Bogdanos DP, Gershwin ME. What is new in primary biliary cirrhosis? Dig Dis. 2012;30 Suppl 1:20-31. doi: 10.1159/000341118. Epub 2012 Oct 11.

  PMID: 23075865 BACKGROUND

Study Officials

• Yomna Abou Elwafa

  Assiut University

  PRINCIPAL INVESTIGATOR

• Adnan Mohamed, Lecturer

  Assiut University

  STUDY DIRECTOR

• Mohamed Mekky, Ass. Prof.

  Assiut University

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident

Study Record Dates

• First Submitted: March 26, 2019
• First Posted: April 2, 2019
• Study Start: August 1, 2019
• Primary Completion: April 1, 2021
• Study Completion: August 31, 2021
• Last Updated: October 6, 2021

Record last verified: 2021-10

Locations

EG (1)